Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URivO biomarker study of nivolumab in previously treated advanced renal cell carcinoma
jRCTs051180102Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in renal cell carcinoma (RCC), sponsored by Ono Pharmaceutical. Primary endpoint: Best Overall Response. Started Apr 2018; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCTs051180102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180102.